SG11201507608PA - Toxoid, compositions and related methods - Google Patents

Toxoid, compositions and related methods

Info

Publication number
SG11201507608PA
SG11201507608PA SG11201507608PA SG11201507608PA SG11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA
Authority
SG
Singapore
Prior art keywords
toxoid
compositions
related methods
methods
Prior art date
Application number
SG11201507608PA
Other languages
English (en)
Inventor
Steven Hauser
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of SG11201507608PA publication Critical patent/SG11201507608PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11201507608PA 2013-03-15 2014-03-14 Toxoid, compositions and related methods SG11201507608PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
SG11201507608PA true SG11201507608PA (en) 2015-10-29

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507608PA SG11201507608PA (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Country Status (13)

Country Link
US (2) US20160045586A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968507A2 (cg-RX-API-DMAC7.html)
JP (1) JP2016516721A (cg-RX-API-DMAC7.html)
KR (1) KR20150133770A (cg-RX-API-DMAC7.html)
CN (1) CN105338997A (cg-RX-API-DMAC7.html)
AR (1) AR095669A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014228956A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907154A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213800A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507608PA (cg-RX-API-DMAC7.html)
TW (1) TWI624474B (cg-RX-API-DMAC7.html)
WO (1) WO2014144567A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
MX388528B (es) 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
EP4444742A4 (en) * 2021-12-06 2025-12-10 Univ Rutgers Compositions and Methods for Treating Cancer
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
JP2010534622A (ja) 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Also Published As

Publication number Publication date
KR20150133770A (ko) 2015-11-30
EP2968507A2 (en) 2016-01-20
CA2907154A1 (en) 2014-09-18
JP2016516721A (ja) 2016-06-09
WO2014144567A2 (en) 2014-09-18
TW201514197A (zh) 2015-04-16
WO2014144567A3 (en) 2014-12-04
US20160045586A1 (en) 2016-02-18
BR112015023332A2 (pt) 2017-08-22
HK1213800A1 (zh) 2016-07-15
CN105338997A (zh) 2016-02-17
TWI624474B (zh) 2018-05-21
AR095669A1 (es) 2015-11-04
US20180028637A1 (en) 2018-02-01
AU2014228956A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
GB2527241B (en) Compositions and methods
IL286759A (en) Therapeutic methods and preparations
GB201308072D0 (en) Compositions and methods
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
EP2951283A4 (en) Compositions and methods
ZA201603237B (en) Pesticidal compositions and related methods
IL244641A0 (en) Nucleotide-modified cytidine-5-carboxamide preparations and related methods
SG11201601138PA (en) Certain chemical entities, compositions, and methods
ZA201603227B (en) Pesticidal compositions and related methods
IL245035A0 (en) Pesticides and related methods
ZA201603229B (en) Pesticidal compositions and related methods
GB201305813D0 (en) Compositions and methods
PL2988764T3 (pl) Kompozycje przeciwłupieżowe i sposoby ich zastosowania
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
IL245034A0 (en) Pesticides and related methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
ZA201603241B (en) Pesticidal compositions and related methods
HUE037525T2 (hu) Kis sejtmagvacska RNS (SNORNA), készítmények és alkalmazások
SG11201604904XA (en) Detergent and rinse-aid compositions and methods
EP2952519A4 (en) PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
SG11201507578PA (en) Toxoid, compositions and related methods
PT2980096T (pt) Métodos de preparação de 2,3,5 tri-hidroxi-androst-6-ona e utilização do mesmo
GB201322617D0 (en) Methods and compositions